Getting “Patient Satisfaction” from Arthritis Health Care
To celebrate Arthritis Awareness Month in Canada, in this issue of JointHealth™ insight, we highlight three international surveys that have helped identify gaps in arthritis models of care from the patient perspective. We want to know what you think. Please complete the three mini surveys in this month’s JointHealth™ insight. Your responses will help drive our 2018 information and education programs to support patients and improve the way health care is delivered by the rheumatologists, allied health professionals, health policy decision makers and others who provide care to Canadians with all types of arthritis.
In this issue, you will also:
Read about the model of care for rheumatoid arthritis
Find a Letter to the Editor template to increase awareness about arthritis in your community
Arthritis Consumer Experts (ACE) is celebrating Arthritis Awareness Month with the #ArthritisMadLibs Twitter Project. The goal is to help others understand the impact of arthritis and make informed decisions about the development of new arthritis programs that will benefit patients and their caregivers.
#ArthritisMadLibs is a chance to re-write the arthritis patient story during Arthritis Awareness Month – one word at a time. On the Labour Day long weekend, the #ArthritisMadLibs hashtag garnered 329.892K impressions, 135 Tweets, 24 participants – averaging 2 Tweets per hour and 6 Tweets per participant.
Since September 1, #ArthritisMadLibs had 910.103K impressions, 379 Tweets, 46 participants – averaging 1 Tweet per hour and 8 Tweets per participant. We thank the patients, health care professionals, patient groups, and researchers who have engaged with us thus far. Our engagement rate on @ACEJointHealth’s Twitter account is at an impressive rate of 2.8% engagement rate (34 link clicks, 179 retweets, 235 likes, 138 replies) – a significantly high engagement rate compared to the average Twitter engagement rate of .7% for the top 25 brands on Twitter. Social media is a tricky business and who you follow, who you have following you, and how many followers you have can affect these statistics but for a grassroot patient organization, we are pretty proud of the #ArthritisMadLibs and its participants and supporters!
Here is a summary of the #ArthritisMadLibs (thus far) and some of our favourite Twitter moments:
Working with your physiotherapist to treat your arthritis pain and symptoms
Physiotherapy is often part of a well-balanced treatment plan for many of the more than 100 types of arthritis. It focuses on maintaining, restoring or improving physical function as well as preventing and managing pain, through the use of non-medication treatments.
When choosing a physiotherapist, it is important to look for someone who has experience treating your type of arthritis, if possible. As well, it is important that you feel comfortable with your therapist, and that you relate well on a personal level.
A physiotherapist will examine your body, and assess things like joint range-of-motion, muscle strength, and swelling or instability in affected joints. A physiotherapist will also likely look at any diagnostic imaging-like x-rays-that you have had done, as well as results from any laboratory testing-for example, blood tests or joint aspirations. Finally, the therapist will want to hear from you about your symptoms, mobility, and changes in your body. Then, using the assessment above, the physiotherapist develops a treatment plan that is specifically tailored to the client’s needs. Some of the treatments used by physiotherapists include: Continue reading →
#ArthritisMadLibs is a chance to re-write the arthritis patient story during Arthritis Awareness Month – one word at a time.
Arthritis Consumer Experts (ACE) is celebrating Arthritis Awareness Month with the #ArthritisMadLibs Twitter Campaign. The goal is to help others understand the impact of arthritis and make informed decisions about the development of new arthritis programs that will benefit patients and their caregivers.
Mad Libs is a word game where key words in a sentence are left intentionally blank for others to substitute with their own words. As we continue to learn from the global arthritis patient surveys, communications is critical between patients and their doctors, rheumatologists, nurses, pharmacists, friends, colleagues and researchers. #ArthritisMadLibs is a chance to re-write the arthritis patient story – one word at a time.
During Arthritis Awareness Month, ACE will be tweeting daily with 5 themed Mad Libs. The themes are patients, work, family and friends, healthcare professionals, and animals. To participate, please follow hashtag #ArthritisMadLibs on our Twitter account @ACEJointHealth. If you do not have a Twitter account but would like to participate, you can follow our Twitter feed on the Arthritis Consumer Experts website (www.jointhealth.org) and email your answers to firstname.lastname@example.org. To drive the campaign, please like, retweet, and reply on Twitter. Arthritis Broadcast Network will be providing a weekly summary of the Mad Libs.
A biosimilar version of etanercept based upon the reference product etanercept (Enbrel®), etanercept (Erelzi®) was issued a Notice of Compliance by Health Canada on April 5, 2017 for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
We apologize for this oversight. Please kindly make this correction to the printed copy you may have recently received in the mail if you are a print subscriber.
Yukon, Ontario, and British Columbia have all recently added biosimilar etanercept (Brenzys®) to their provincial formularies for the treatment of rheumatoid arthritis and ankylosing spondylitis. The following clinical criterion and conditions must be met:
clinical criterion: for use in patients for whom etanercept is considered to be the most appropriate treatment option.
conditions: Brenzys® must be reimbursed in a manner similar to Enbrel®; and, the cost of treatment with Brenzys® should provide significant cost savings for jurisdictions compared with the cost of treatment with Enbrel®
On October 25, 2016, biosimilar etanercept (Brenzys®) was approved for the treatment of rheumatoid arthritis and ankylosing spondylitis. Brenzys® is a biosimilar to the Canadian authorized reference product, Enbrel®. Both contain the active pharmaceutical ingredient, etanercept. Brenzys® works by targeting the tumor necrosis factor alpha (TNFA) molecule and is given by subcutaneous injection. Please click here to read the details of Health Canada’s decision summary for Brenzys®.